Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour
Gastrointestinal stromal tumour (GIST) is the most common sarcoma and can be seen in any part of the gastrointestinal tract. The effect of tyrosine kinase inhibitors varies with mutation status in receptor tyrosine kinase KIT and in platelet-derived growth factor receptor A (PDGFRA). This case prese...
Guardado en:
Autores principales: | Charlotte Brinch, Marie Dehnfeld, Estrid Hogdall, Tim Svenstrup Poulsen, Anders Toxvaerd, Gina Al-Farra, Magnus Bergenfeldt, Anders Krarup-Hansen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Karger Publishers
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/486d5e758ceb4949b7c1db703d5bedbf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
por: Daria A. Filonenko, et al.
Publicado: (2021) -
Gastrointestinal Stromal Tumors (GISTs): Single Center Experience Observed in a Small Series of Cases
por: Manterola,Carlos, et al.
Publicado: (2016) -
Deep Convolutional Neural Networks Detect Tumor Genotype from Pathological Tissue Images in Gastrointestinal Stromal Tumors
por: Cher-Wei Liang, et al.
Publicado: (2021) -
Sorafenib induced acral pigmentation: A new entity
por: Mrinal Gupta, et al.
Publicado: (2015) -
Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
por: Liming Zheng, et al.
Publicado: (2021)